Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD) - iPOD

Radboud University Nijmegen Medical Centre0 个研究点开始时间: 2008年11月24日最近更新: 2012年8月14日

适应症

试验速览

暂无简介。

•1. Patients with CGD, rendering them at risk for invasive fungal infections, hence requiring antifungal prophylaxis.
•2. Patient is at least 2 years of age and younger than 17 years of age on the day of the first dosing.
•3. Parents or legal representative, and children where appropriate, willing and able to give informed consent.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Patients suspected of an invasive fungal infection.
•2. Therapy with any medicinal product for which an effect on PSZ is expected (see Clinical Trial Protocol, appendix B, Table 1). If patient is undergoing therapy with any medicinal product which may be effected by PSZ, the patient is included on condition that the investigator judges that the effects are not clinically relevant (see Clinical Trial Protocol, appendix B, Table 2). This should be clearly recorded.
•3. Documented history of sensitivity/idiosyncrasy to PSZ.
•4. Results of serum biochemistry and hematology testing are not higher than 3x the upper limit of normal (see Clinical Trial Protocl, appendix A). If the results exceed these limits, the subject is included on condition that the investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
•5. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
•6. Relevant history or presence of cardiovascular disorder or renal and hepatic disorder.
•7. History of or current abuse of drugs, alcohol or recreational substances.
•8. Participation in a trial with an investigational drug within 60 days prior to the first dose.

发起方

Radboud University Nijmegen Medical Centre